RHHBY
Roche Holding AG
Set alert
61.27 USD +0.50 +0.82%
60.79 Day range 61.43
40.15 52-week range 61.27
- YTD
- +18.81%
- 1 year
- +50.87%
- Open
- 61.12
- Prev close
- 60.77
- Mkt cap
- 390.54B
- Vol
- 202.17K
- Avg vol
- 1.77M
- EPS
- 2.41
- P/E
- 25.42
More statistics
- Low
- 60.79
- High
- 61.43
- Earnings
- Feb 4, 2027
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 1.49.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 1.49 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | 1.58 | 1.66 | +0.08 | +5.06% |
| Jan 29, 2026 | Dec 31, 2025 | 1.35 | 1.36 | +0.01 | +0.74% |
| Jul 24, 2025 | Jun 30, 2025 | 1.62 | 1.74 | +0.12 | +7.41% |
| Jan 30, 2025 | Dec 31, 2024 | 1.17 | 1.18 | +0.01 | +0.85% |
| Jul 22, 2024 | Jun 30, 2024 | 1.30 | 1.43 | +0.13 | +10.00% |
News
- Roche: Valuation Leaves Limited Upside
- Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
- Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
- Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- Breakfast News: Science Strikes Back at Cancer
- Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
- Roche says divarasib cut risk of death 44% in lung cancer trial
- Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
- Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Your note
Sign in to keep a note on RHHBY — it syncs with the Stock Master app.